Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States

Antimicrob Agents Chemother. 2002 Aug;46(8):2540-5. doi: 10.1128/AAC.46.8.2540-2545.2002.

Abstract

The Infectious Diseases Society of America advocates trimethoprim-sulfamethoxazole (SXT) as initial therapy for females with acute uncomplicated bacterial cystitis in settings where the prevalence of SXT resistance does not exceed 10 to 20%. To determine trends in the activities of SXT, ampicillin, ciprofloxacin, and nitrofurantoin among urine isolates of Escherichia coli from female outpatients, susceptibility testing data from The Surveillance Network (TSN) Database-USA (n = 286,187) from 1995 to 2001 were analyzed. Resistance rates among E. coli isolates to ampicillin (range, 36.0 to 37.4% per year), SXT (range, 14.8 to 17.0%), ciprofloxacin (range, 0.7 to 2.5%), and nitrofurantoin (range, 0.4 to 0.8%) varied only slightly over this 7-year period. Ciprofloxacin was the only agent studied that demonstrated a consistent stepwise increase in resistance from 1995 (0.7%) to 2001 (2.5%). In 2001, SXT resistance among E. coli isolates was >10% in all nine U.S. Bureau of the Census regions. At institutions testing > or =100 urinary isolates of E. coli (n = 126) in 2001, ampicillin (range, 27.3 to 98.8%) and SXT (range, 7.5 to 47.1%) resistance rates varied widely while ciprofloxacin (range, 0 to 12.9%) and nitrofurantoin (range, 0 to 2.8%) resistance rates were more consistent. In 2001, the most frequent coresistant phenotypes were resistance to ampicillin and SXT (12.0% of all isolates; 82.3% of coresistant isolates) and resistance to ampicillin, ciprofloxacin, and SXT (1.4% of all isolates; 9.9% of coresistant isolates). Coresistance less frequently included resistance to nitrofurantoin (3.5% of coresistant isolates) than resistance to ciprofloxacin (15.8%), SXT (95.7%), and ampicillin (98.1%). In conclusion, among urinary isolates of E. coli from female outpatients in the United States, national resistance rates to SXT were relatively consistent (14.8 to 17.0%) from 1995 to 2001 but demonstrated considerable regional and institutional variation in 2001. Therapies other than SXT may need to be considered in some locations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ampicillin / pharmacology
  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents, Urinary / pharmacology*
  • Ciprofloxacin / pharmacology
  • Databases, Factual
  • Drug Resistance, Microbial
  • Escherichia coli / drug effects*
  • Escherichia coli / genetics
  • Escherichia coli Infections / epidemiology
  • Escherichia coli Infections / microbiology*
  • Female
  • Geography
  • Humans
  • Microbial Sensitivity Tests
  • Nitrofurantoin / pharmacology
  • Outpatients
  • Penicillins / pharmacology
  • Phenotype
  • Trimethoprim, Sulfamethoxazole Drug Combination / pharmacology
  • United States / epidemiology
  • Urinary Tract Infections / epidemiology
  • Urinary Tract Infections / microbiology*

Substances

  • Anti-Infective Agents
  • Anti-Infective Agents, Urinary
  • Penicillins
  • Ciprofloxacin
  • Ampicillin
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Nitrofurantoin